Eloxx Pharmaceuticals Receives the US FDA’s IND Clearance for Exaluren to Treat Nonsense-Mutation ADPKD

Shots: The US FDA has cleared Eloxx Pharmaceuticals’ IND for exaluren, an oral small-molecule ribosomal modulator, to treat nonsense-mutation autosomal dominant polycystic kidney disease (ADPKD), enabling the P-II EXPRESS trial to open US sites The global P-II EXPRESS trial will randomize ~60 adults with PKD1 or PKD2 nonsense mutations (1:1) to exaluren or PBO for 52wks, assessing annualized change in htTKV as its 1EP; first dosing is expected in Q3’27 with topline data in H1’29 Exaluren holds ODD for ADPKD & Alport syndrome in the US & EU Ref: PR Newswire  |   Image: Eloxx Pharmaceuticals  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Eloxx Pharmaceuticals Receives the US FDA’s IND Clearance for Exaluren to Treat Nonsense-Mutation ADPKD appeared first on PharmaShots.